NCT00397943View on ClinicalTrials.gov

Safety and Immunogenicity of 2 Formulations of Tuberculosis Vaccine GSK692342 Given at 0,1 Months to Healthy Adults

PHASE2CompletedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

November 15, 2006

Primary Completion Date

December 1, 2009

Study Completion Date

December 1, 2009

Conditions
Tuberculosis
Interventions
BIOLOGICAL

GSK's candidate Mycobacterium tuberculosis vaccine 692342

Intramuscular injection, 2 doses at 0, 1 month

BIOLOGICAL

Comparator vaccine with recombinant Mycobacterium tuberculosis antigen and adjuvant system

Intramuscular injection, 2 doses at 0, 1 month

BIOLOGICAL

Comparator vaccine with recombinant Mycobacterium tuberculosis antigen and physiological saline

Intramuscular injection, 2 doses at 0, 1 month

BIOLOGICAL

Control vaccine with the adjuvant system.

Intramuscular injection, 2 doses at 0, 1 month

Trial Locations (1)

9000

GSK Investigational Site, Ghent

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00397943 - Safety and Immunogenicity of 2 Formulations of Tuberculosis Vaccine GSK692342 Given at 0,1 Months to Healthy Adults | Biotech Hunter | Biotech Hunter